Health and Healthcare

Amgen : AMGN

All Amgen Articles

708 Articles

Trey Thoelcke | Mar 14, 2014 at 8:50 AM EDT

Jefferies’ Cheapest Health Care Stocks to Buy

In a new report out from Jefferies, the analysts posted a complete list of the cheapest, on a P/E basis,…

Trey Thoelcke | Mar 13, 2014 at 9:15 AM EDT

Deutsche Bank’s Eight True Dividend Growth Stocks to Buy Now

In a new research report from Deutsche Bank, the equity strategists point that the companies that are maintaining and increasing…

Trey Thoelcke | Mar 12, 2014 at 9:00 AM EDT

Low P/E High-Dividend Blue Chip Leaders to Buy Now

The pricier the stock market gets, the more important it is for investors to keep a close eye on what…

Trey Thoelcke | Mar 12, 2014 at 7:10 AM EDT

Short Sellers Retreat From Biotech Stocks Again

Biotech and emerging pharmaceutical stocks continue to be hot, but short sellers shied away from many of them in late…

Trey Thoelcke | Feb 27, 2014 at 7:00 AM EST

Short Sellers Return to Biotech Stocks

After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical…

Trey Thoelcke | Feb 12, 2014 at 6:50 AM EST

Short Sellers Shy Away From Biotechs

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers…

Paul Ausick | Feb 5, 2014 at 8:20 AM EST

Merck Earnings Fail to Dazzle, but the Company’s Story Remains Strong

Before the markets opened Wednesday morning, drug giant Merck & Co. reported fourth-quarter and full-year 2013 results that failed to…

cgblaine22 | Jan 29, 2014 at 12:10 PM EST

Why Caution Is Prevailing in Biotechs Into and After Earnings

Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences…

Trey Thoelcke | Jan 29, 2014 at 8:15 AM EST

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large…

Jon C. Ogg | Jan 28, 2014 at 4:13 PM EST

Amgen Nails Earnings, Guidance a Different Story

ThinkstockAmgen Inc. (NASDAQ: AMGN) is the second largest biotech player, and now we have seen its fourth-quarter earnings report. Earnings…

Trey Thoelcke | Jan 22, 2014 at 9:05 AM EST

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we…

Trey Thoelcke | Dec 19, 2013 at 8:30 AM EST

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.

Jon C. Ogg | Nov 21, 2013 at 7:55 AM EST

Eight Big Dividend Hikes Expected Before 2013 Ends

ThinkstockInvestors love dividends, particularly safe and dependable dividends that rise through time. The S&P 500 Index currently has the most…

Jon C. Ogg | Nov 19, 2013 at 11:50 AM EST

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies…

Lee Jackson | Nov 14, 2013 at 9:30 AM EST

Five Prime Takeover Candidates for 2014

ThinkstockMany Wall Street analysts and strategists are forecasting a rise in corporate earnings for the rest of the year and…

1 … 30 31 32 33 34 … 48

Amgen : AMGN

All Amgen Articles

Jefferies’ Cheapest Health Care Stocks to Buy

Deutsche Bank’s Eight True Dividend Growth Stocks to Buy Now

Low P/E High-Dividend Blue Chip Leaders to Buy Now

Short Sellers Retreat From Biotech Stocks Again

Short Sellers Return to Biotech Stocks

Short Sellers Shy Away From Biotechs

Merck Earnings Fail to Dazzle, but the Company’s Story Remains Strong

Why Caution Is Prevailing in Biotechs Into and After Earnings

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Amgen Nails Earnings, Guidance a Different Story

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Eight Big Dividend Hikes Expected Before 2013 Ends

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

Five Prime Takeover Candidates for 2014

If Social Security Cuts Benefits, Here’s Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

AI Architect Earning $1.1M/Year Almost Took on $550K in Debt to Dodge Taxes: ‘I Have No Idea What That Business Is’

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

If Social Security Cuts Benefits, Here’s Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

Amgen : AMGN

All Amgen Articles

Jefferies’ Cheapest Health Care Stocks to Buy

Deutsche Bank’s Eight True Dividend Growth Stocks to Buy Now

Low P/E High-Dividend Blue Chip Leaders to Buy Now

Short Sellers Retreat From Biotech Stocks Again

Short Sellers Return to Biotech Stocks

Short Sellers Shy Away From Biotechs

Merck Earnings Fail to Dazzle, but the Company’s Story Remains Strong

Why Caution Is Prevailing in Biotechs Into and After Earnings

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Amgen Nails Earnings, Guidance a Different Story

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Eight Big Dividend Hikes Expected Before 2013 Ends

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

Five Prime Takeover Candidates for 2014

If Social Security Cuts Benefits, Here’s Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

AI Architect Earning $1.1M/Year Almost Took on $550K in Debt to Dodge Taxes: ‘I Have No Idea What That Business Is’

Featured Reads

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account